RxDoctor Payments DataLook up a doctor →

Hubert Reyes, MD

Family Medicine · Evansville, INNPI 1497957526

Payments from drug & device makers

$3,239,522in general payments, 2019–2025

Across 1,377 payments — averaging $2352.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$656K
  • GSK$554K
  • Boehringer Ingelheim$513K
  • Johnson & Johnson$304K
  • Amgen$278K
  • AbbVie$187K
  • plus $748K from 54 others
$18,603in research payments, 2019–2025

Across 5 payments — averaging $3720.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$19K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer126$656,052
GSK157$554,180
Boehringer Ingelheim34$512,762
Johnson & Johnson65$303,887
Amgen(2 entities)108$277,627
AbbVie198$187,321
Vivus LLC16$136,505
Sanofi US Services Inc.16$131,407
Bristol Myers Squibb13$62,033
Genentech, Inc.23$55,727
Janssen Research & Development, LLC14$52,401
Lexicon Pharmaceuticals, Inc.5$46,717
AstraZeneca(2 entities)42$44,465
Biohaven Pharmaceutical Holding Company Ltd.17$41,218
Sanofi Pasteur Inc.10$31,652
Biogen7$30,537
GRT US Holding, Inc.24$24,727
Regeneron8$24,451
Boehringer Ingelheim International GmbH103$22,303
Merck6$16,078
Radius Health, Inc.33$10,996
Hoffmann-la Roche Limited3$9,800
Chiesi USA, Inc.2$1,310
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC53$733
Otsuka America Pharmaceutical, Inc.28$482
Novo Nordisk33$471
Novartis30$413
Axsome Therapeutics, Inc.27$412
Lilly USA, LLC27$373
Merz North America, Inc.2$262
Takeda Pharmaceuticals U.S.A., Inc.16$226
Almatica Pharma LLC12$199
Amarin Pharma, Inc.22$175
Lundbeck LLC7$145
Esperion Therapeutics, Inc.7$127
Vanda Pharmaceuticals Inc.6$124
Bayer7$109
Biohaven Pharmaceuticals, Inc.5$97
Kowa Pharmaceuticals America, Inc.7$97
Sanofi-aventis U.S. LLC6$87
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$81
Idorsia Pharmaceuticals US Inc5$76
Exact Sciences5$76
Covis Pharma GmbH4$61
Sumitomo Pharma America, Inc.4$60
Sunovion Pharmaceuticals Inc.3$52
E.r. Squibb & Sons, L.L.C.3$43
Teva Pharmaceuticals USA, Inc.2$38
Astellas Pharma US Inc3$37
Corium, LLC2$36
Neurocrine Biosciences, Inc.2$33
Phathom Pharmaceuticals, Inc.2$31
Alkermes, Inc.2$31
Eisai Inc.2$30
Genentech USA, Inc.2$29
Edwards Lifesciences1$26
Dexcom, Inc.1$20
Alnylam Pharmaceuticals Inc.1$16
Shield Therapeutics Inc1$13
Arbor Pharmaceuticals, Inc.1$13

How this compares

$3,239,522 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana →

Medicare billing

Part B allowed, 2024
$202,241
Medicare patients
233
Services billed
10,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Evansville

See the full list for Indiana →

Where these figures come from

Is this you, or does something look wrong? →